H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.
Average dividend payer and fair value.
Share Price & News
How has H. Lundbeck's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LUN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LUN underperformed the Danish Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: LUN underperformed the Danish Market which returned 21.4% over the past year.
Price Volatility Vs. Market
How volatile is H. Lundbeck's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StIs H. Lundbeck (CPH:LUN) A Risky Investment?
3 weeks ago | Simply Wall StIf You Had Bought H. Lundbeck (CPH:LUN) Shares Five Years Ago You'd Have Made 83%
1 month ago | Simply Wall StIs H. Lundbeck A/S' (CPH:LUN) Latest Stock Performance A Reflection Of Its Financial Health?
Is H. Lundbeck undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LUN (DKK247.7) is trading below our estimate of fair value (DKK577.39)
Significantly Below Fair Value: LUN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LUN is poor value based on its PE Ratio (25.6x) compared to the Pharmaceuticals industry average (24.1x).
PE vs Market: LUN is poor value based on its PE Ratio (25.6x) compared to the Danish market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: LUN is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: LUN is overvalued based on its PB Ratio (3.5x) compared to the XE Pharmaceuticals industry average (3.2x).
How is H. Lundbeck forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUN's forecast earnings growth (31% per year) is above the savings rate (0.3%).
Earnings vs Market: LUN's earnings (31% per year) are forecast to grow faster than the Danish market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LUN's revenue (4.6% per year) is forecast to grow slower than the Danish market (6.5% per year).
High Growth Revenue: LUN's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LUN's Return on Equity is forecast to be low in 3 years time (17.5%).
How has H. Lundbeck performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LUN has high quality earnings.
Growing Profit Margin: LUN's current net profit margins (11.1%) are lower than last year (20.3%).
Past Earnings Growth Analysis
Earnings Trend: LUN has become profitable over the past 5 years, growing earnings by 57.3% per year.
Accelerating Growth: LUN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LUN had negative earnings growth (-46.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).
Return on Equity
High ROE: LUN's Return on Equity (13.6%) is considered low.
How is H. Lundbeck's financial position?
Financial Position Analysis
Short Term Liabilities: LUN's short term assets (DKK8.7B) exceed its short term liabilities (DKK7.9B).
Long Term Liabilities: LUN's short term assets (DKK8.7B) do not cover its long term liabilities (DKK12.9B).
Debt to Equity History and Analysis
Debt Level: LUN's debt to equity ratio (73.7%) is considered high.
Reducing Debt: LUN's debt to equity ratio has increased from 23% to 73.7% over the past 5 years.
Debt Coverage: LUN's debt is not well covered by operating cash flow (18.9%).
Interest Coverage: LUN's interest payments on its debt are well covered by EBIT (39.6x coverage).
What is H. Lundbeck current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LUN's dividend (1.66%) is higher than the bottom 25% of dividend payers in the Danish market (1.39%).
High Dividend: LUN's dividend (1.66%) is low compared to the top 25% of dividend payers in the Danish market (3.4%).
Stability and Growth of Payments
Stable Dividend: LUN's dividend payments have been volatile in the past 10 years.
Growing Dividend: LUN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (42.4%), LUN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: LUN's dividends in 3 years are forecast to be well covered by earnings (30.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Deborah Dunsire (58yo)
Dr. Deborah Dunsire, M.D. serves as Chief Executive Officer and President at H. Lundbeck A/S since September 2018 and served as its Interim Executive Vice President of R&D since January 2019 until February ...
CEO Compensation Analysis
Compensation vs Market: Deborah's total compensation ($USD3.22M) is above average for companies of similar size in the Danish market ($USD2.23M).
Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|President & CEO||1.83yrs||ø21.20m||0.0018% DKK860.3k|
|Executive VP & CFO||13.17yrs||ø10.20m||0.022% DKK10.5m|
|Executive Vice President of Product Development & Supply||1.5yrs||ø8.90m||0.018% DKK8.6m|
|Executive Vice President of Commercial Operations||2.67yrs||ø8.30m||0.00020% DKK97.8k|
|Executive Vice President of R&D||1.5yrs||ø6.84m||no data|
|Chief Specialist & VP of Investor Relations||no data||no data||no data|
|Senior Director of Corporate Communication||no data||no data||no data|
|Executive VP and Head of People & Communication||0.83yr||no data||0.00062% DKK303.1k|
|Senior Vice President of International Markets||no data||no data||no data|
|Executive Vice President of North America||2.67yrs||no data||no data|
Experienced Management: LUN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Independent Director||3.5yrs||no data||no data|
|Independent Director||2.33yrs||no data||0.0018% DKK860.3k|
|Independent Chairman||4.25yrs||no data||0.010% DKK4.9m|
|Deputy Chairman||5.5yrs||no data||0.0044% DKK2.2m|
|Independent Director||2.33yrs||no data||no data|
|Director||5.5yrs||no data||0.0076% DKK3.7m|
|Employee Representative Director||2.5yrs||no data||no data|
|Employee Representative Director||2.33yrs||no data||no data|
|Employee Representative Director||2.33yrs||no data||no data|
Experienced Board: LUN's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
H. Lundbeck A/S's company bio, employee growth, exchange listings and data sources
- Name: H. Lundbeck A/S
- Ticker: LUN
- Exchange: CPSE
- Founded: 1915
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø48.883b
- Shares outstanding: 198.71m
- Website: https://www.lundbeck.com
Number of Employees
- H. Lundbeck A/S
- Ottiliavej 9
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HLUK.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1999|
|LUN||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Ordinary Shares||DK||DKK||Jun 1999|
|LDB||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1999|
|0ND5||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||DKK||Jun 1999|
|LUNC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||DKK||Jun 1999|
|HLUY.Y||OTCPK (Pink Sheets LLC)||SPONS ADR L 1||US||USD||May 2012|
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/09 20:50|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.